Physician profile
Summera Qamar
NPI 1891083937
$1,056.21
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.17 · 2020: $170 · 2021: $226 · 2022: $484 · 2023: $95.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $95.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $95.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $223.55 | 2020-2023 | Repatha, Otezla |
| Novo Nordisk INC | $156.75 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $133.90 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $82.95 | 2021-2023 | Austedo |
| Biohaven Pharmaceutical Holding Company LTD. | $79.36 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $78.55 | 2020-2022 | |
| Glaxosmithkline, LLC. | $61.54 | 2021-2023 | Arexvy |
| Janssen Pharmaceuticals, INC | $45.85 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $45.42 | 2019-2020 | |
| Lilly USA, LLC | $30.32 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.16 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.79 | 2020 | |
| Esperion Therapeutics, INC. | $14.63 | 2021 | |
| Pfizer INC. | $14.09 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.92 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $13.59 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $12.81 | 2019 | |
| Kci USA, INC. | $11.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Summera Qamar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.